Hoffmann-la Roche

This study tested if adding the immunotherapy drug atezolizumab to standard chemotherapy before surgery helps people with early-stage, operable non-small cell lung cancer. Researchers wanted to see if this combination could better shrink tumors and prevent the cancer from coming …

This study tested several immunotherapy-based drug combinations for people with advanced HR-positive, HER2-negative breast cancer that had worsened despite standard hormone therapy. It involved 144 participants who received different combinations of drugs, including a standard ho…

This study tested whether a new monthly injection (Mircera) could work as well as a standard weekly injection (epoetin alfa) to maintain healthy red blood cell levels in people with anemia from kidney failure on dialysis. Over 200 patients who were already receiving the weekly tr…

This study tested several different combinations of immunotherapy drugs for people with metastatic pancreatic cancer that has spread. It involved 341 participants who had either received no prior treatment or one prior treatment. The main goals were to see if the drug combination…

This study aimed to check the safety of a two-drug combination (atezolizumab plus nab-paclitaxel) for people with a hard-to-treat, advanced form of breast cancer that had spread. It involved 184 participants whose cancer tested positive for a specific marker (PD-L1) and who had n…

This study tested a monthly injection called Mircera to treat anemia (low red blood cells) in adults with kidney disease who were not yet on dialysis. The goal was to see if the injection could safely raise and keep patients' hemoglobin levels in a healthy target range. About 75 …

This large, completed Phase 3 trial tested whether adding a new drug called tiragolumab to an existing immunotherapy (atezolizumab) works better than the immunotherapy alone for people with a specific type of advanced lung cancer who haven't had prior treatment. The study involve…

This study tested whether adding a new drug called tiragolumab to an existing immunotherapy (atezolizumab) was more effective and safe than using atezolizumab alone. It involved 172 women with advanced cervical cancer that had returned or spread and had stopped responding to prio…

This study followed 322 adults with moderate to severe rheumatoid arthritis for one year after they started treatment with the drug tocilizumab (Actemra/RoActemra) in their regular doctor's care. The goal was to see how well the drug worked to control disease activity and reduce …

This study tested several different drug combinations for people with advanced stomach or gastroesophageal cancer who hadn't received prior treatment. It was designed to be flexible—adding new treatments as they became available and stopping ones that didn't work well or caused t…

This study tested two different doses of an experimental immunotherapy drug called RO7247669 in people with advanced melanoma that cannot be removed by surgery. The goal was to see how well the drug works, how safe it is, and to pick the best dose for future research. The trial i…

This study tested a preventive treatment called emicizumab in people with mild or moderate hemophilia A who do not have inhibitors. The goal was to see if regular injections could safely reduce the number of bleeding episodes. Researchers measured how often participants bled and …

This study tested several different immunotherapy-based drug combinations for people with advanced bladder cancer that had worsened after standard chemotherapy. It involved 272 participants and was designed to quickly find and stop treatments that didn't work well while advancing…

This study tested a new, faster way to give two important breast cancer drugs. It compared giving the drugs as a single injection under the skin to the standard method of giving them slowly into a vein. The goal was to see if the new method worked just as well and was safe for Ch…

This study tested whether a new two-drug immunotherapy combination (atezolizumab + tiragolumab) works better than the standard single immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The trial involved 829 patients…

This study tested whether adding a new drug called vamikibart to a standard eye injection (ranibizumab) works better for diabetic macular edema (DME) than the standard injection alone. DME is a swelling in the back of the eye that can cause vision loss in people with diabetes. Th…

This study tested the safety and how the body processes the drug risdiplam in 174 adults and children with spinal muscular atrophy (SMA), a genetic muscle-wasting disease. All participants had previously tried other SMA treatments. The main goal was to see if risdiplam was safe a…

This large, completed Phase 3 trial tested whether adding a new drug called tiragolumab to a standard treatment could better control advanced small cell lung cancer. It involved 490 patients who had not yet received chemotherapy for their widespread disease. The study compared th…

This completed Phase 3 study tested whether regular injections of an experimental drug called vamikibart into the eye could reduce swelling and improve vision in people with uveitic macular edema. The trial involved 256 participants who received either the real drug or a sham (fa…

This study tested whether adding a targeted drug called polatuzumab vedotin to a standard chemotherapy combination (R-GemOx) could help people with an aggressive type of lymphoma that had come back or stopped responding to prior treatments. It involved 270 adults whose cancer had…

This large, completed Phase 3 trial tested whether adding two new immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy could better control advanced esophageal cancer that cannot be surgically removed. The study involved 461 patients and directly compared t…

This early-phase study tested different combinations of immunotherapy and chemotherapy drugs in patients with advanced head and neck cancer that could be surgically removed. The goal was to see if these treatments given before surgery could shrink or even eliminate the tumor. The…

This study aimed to find out if patients and healthcare staff prefer a new under-the-skin injection for a lung cancer drug over the standard intravenous (IV) infusion. 179 adults with non-small cell lung cancer tried both methods. The main goal was to measure which way of getting…

This study aimed to check the long-term safety of a drug called faricimab for people with wet age-related macular degeneration, a leading cause of vision loss. Over 1,000 patients who had already completed earlier studies received the drug via eye injections at personalized inter…

This study tested a new medication called vamikibart, given as an injection into the eye, for people with diabetic macular edema (DME), a condition that causes vision loss. It compared the new injection to an existing treatment to see if it was better at improving or preserving e…

This study tested a drug called alogabat in children and teenagers with Angelman syndrome, a rare genetic disorder. The main goals were to see how the drug moves through the body, if it is safe, and if it changes brain wave patterns. Forty-eight participants aged 5 to 17 took the…

This early-stage study tested a new experimental immunotherapy drug called eciskafusp alfa. Researchers gave it to 189 adults with advanced solid tumors, both by itself and combined with an existing drug (atezolizumab), to check its safety and find the right dose. The main goals …

This study tested several different immunotherapy-based drug combinations for people with advanced stomach or esophageal cancer that had spread or could not be removed by surgery. It involved 214 patients, including some receiving their first treatment and others who had already …

This study tested the safety and how the body processes a new two-drug immunotherapy combination for people with advanced solid cancers that had spread or returned. The trial involved 64 participants with specific tumor characteristics who had not received similar immune-based tr…

This study tested whether adding an experimental drug (tiragolumab) to an existing immunotherapy (atezolizumab) works better than the immunotherapy alone for people with advanced head and neck cancer that has returned or spread. It involved 123 adults whose cancer had a specific …

This study observed how well the drug MIRCERA worked to control anemia in people with moderate-to-severe kidney disease who were not yet on dialysis. Researchers followed 144 patients in their normal clinical care for up to a year to see if the drug safely kept their hemoglobin (…

This early-stage study tested a new cancer drug called RO7623066, both alone and combined with other treatments, in 116 patients with advanced solid tumors. The main goals were to find the safest dose and see how the body processes the drug. Researchers also looked for early sign…

This study tested whether a new preventive drug called emicizumab could reduce the number of bleeding episodes in people with hemophilia A. It involved 85 participants, including teens and adults, who were prone to frequent bleeds. They were given either the drug as a weekly or m…

This study followed patients who had already completed earlier trials of faricimab, a medication injected into the eye to treat diabetic macular edema (swelling in the back of the eye). Researchers monitored 1,479 patients for long-term side effects, particularly looking for any …

This large, completed study tested whether adding a drug called atezolizumab to standard chemotherapy could help patients with a hard-to-treat, aggressive form of breast cancer that had returned or spread. It involved nearly 600 patients whose cancer had come back quickly after p…

This small, completed study tested whether a one-month course of an experimental drug called TRO19622 was safe and could improve liver health in people with NASH, a type of fatty liver disease. Twenty-two adults with confirmed NASH received either the drug or a placebo. The main …

This study tested a new drug, PF-06480605, to see if it could help adults with moderate to severe ulcerative colitis. Researchers compared different doses of the drug against a placebo in 246 participants over a 12-week period. The main goal was to see if the drug could bring the…

This study tested whether adding the experimental drug tiragolumab to the existing drug atezolizumab could better prevent lung cancer from returning in people who had already undergone surgery and chemotherapy. It involved 56 people with early-stage non-small cell lung cancer tha…

This study tested whether giving patients with operable liver cancer a short course of immune-boosting drug combinations before surgery could help shrink their tumors. The goal was to see if this 'neoadjuvant' approach could lead to better surgical outcomes and lower the chance o…

This study tested a new combination of drugs for people with an aggressive type of lymphoma (DLBCL) that had come back or stopped responding to their first treatment. The goal was to see if adding a new drug called glofitamab to a standard chemotherapy regimen could effectively s…

This study tested whether a new drug called vamikibart, given as an injection into the eye, could safely reduce swelling and improve vision in people with uveitic macular edema. It involved 245 participants who received either the real injection or a sham (pretend) procedure. The…

This completed Phase 3 trial tested two different drug combinations for people with chronic lymphocytic leukemia (CLL) who also had other health problems and needed treatment for the first time. It compared a newer combination (obinutuzumab + venetoclax) against an older standard…

This study tested whether adding a new drug called tiragolumab to a standard immunotherapy and chemotherapy regimen works better than the current standard treatment for people with advanced non-small cell lung cancer who haven't had prior treatment. It involved 542 participants w…

This study tested several new combination drug therapies to see if they could help control and potentially clear chronic Hepatitis B infection. It involved 281 adults with stable liver function who were already on standard antiviral medication. The main goal was to see if the new…

This study tested several different immunotherapy combinations for people with advanced non-small cell lung cancer that has spread. It involved 314 patients who were either newly diagnosed or whose cancer had progressed after previous treatment. The goal was to find which combina…

This completed Phase 3 trial compared a newer drug combination (venetoclax + obinutuzumab) against standard chemotherapy regimens for adults with previously untreated chronic lymphocytic leukemia (CLL). The goal was to see which approach was more effective at controlling the canc…

This study tested the safety and effectiveness of a two-drug combination (atezolizumab and bevacizumab) for patients with advanced liver cancer that cannot be removed by surgery. It involved 152 patients who had not received any prior drug treatment for their cancer. The main goa…

This study tested whether combining two drugs (atezolizumab and cabozantinib) works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has spread and worsened despite prior treatments. It involved 366 patients and aimed to see i…

This study tested whether personalized cancer treatment based on genetic testing works better than standard chemotherapy for cancers where doctors can't find the original source. It involved 529 patients whose cancer had responded to initial chemotherapy. Researchers compared how…

This large, completed study tested whether adding a new drug called pertuzumab to the standard treatment (chemotherapy plus trastuzumab) was better at preventing breast cancer from coming back after surgery. It involved over 4,800 women with a specific type of operable, HER2-posi…

This study followed over 1,000 people with multiple sclerosis (MS) who had already been taking ocrelizumab in earlier Roche-sponsored trials. The goal was to gather more information on the long-term effectiveness and safety of the drug. Participants continued receiving ocrelizuma…

This study observed how well the breast cancer drug T-DM1 works and how safe it is in everyday medical practice in China. It followed 178 patients with advanced HER2-positive breast cancer who had already tried other treatments. Researchers tracked side effects and how long the t…

This study tested a new, more convenient way to give an existing lung cancer drug. Researchers compared giving the medicine as an under-the-skin injection to the standard method of an IV drip. The goal was to see if the injection worked just as well and was safe for people with a…

This study followed a small group of children in France with juvenile arthritis for two years to check the long-term safety of a drug called tocilizumab. The children had already been taking the drug in a previous study and continued receiving it by IV every four weeks. The main …

This study aimed to find out if patients with a specific type of breast cancer (HER2-positive) preferred receiving a two-drug treatment at home or in a hospital. Over 300 participants tried both methods. The main goal was to measure which setting patients liked better, focusing o…

This study followed 1,710 people with multiple sclerosis (MS) who were prescribed the medication ocrelizumab as part of their regular care. The goal was to see how well the drug works in real-world settings by tracking changes in symptoms like fatigue, mobility, and cognition, as…

This international study tested whether a blood test called liquid biopsy could help doctors diagnose advanced lung or gastrointestinal cancer faster than standard tissue biopsies. Researchers compared the time it took to get results using both methods in 463 newly diagnosed pati…

This study tested tumor samples from 470 cancer patients to identify specific biological markers in their cancer cells. The goal was to use this information to determine which patients might qualify for future Roche treatment trials. The study did not provide treatment itself but…

This study aimed to measure the thickness of specific eye tissues in patients with two common vision conditions (neovascular age-related macular degeneration and diabetic macular edema) and compare them to healthy volunteers. Researchers used a special imaging scan to take these …

This study aimed to understand if a multiple sclerosis (MS) medication called ocrelizumab passes into breastmilk and affects breastfeeding infants. Researchers measured the drug levels in breastmilk and checked the babies' immune cells and responses to standard childhood vaccines…

This study aimed to understand if a multiple sclerosis medication called ocrelizumab passes from a pregnant mother to her baby. Researchers followed 70 infants whose mothers took the drug around the time of pregnancy to check the babies' immune cell levels and see if they respond…